China Clinical Evaluation Report
A Clinical Evaluation Report (CER) is a document required by the National Medical Products Administration (NMPA) for the registration of medical devices and in vitro diagnostic (IVD) products in China. Clinical evidence is crucial in this process, as it supports the safety, clinical performance, and effectiveness of the device. It involves the ongoing evaluation and analysis of clinical data using scientific methods to demonstrate the safety, clinical performance, and/or effectiveness of a device within its intended use.
Understanding Clinical Evaluation in China
Clinical evaluation is a critical step in the registration process for medical devices in China. It involves validating whether the product meets its intended use requirements or scope of application. This process requires a thorough review of clinical literature, clinical experience data, and clinical trials. For Class II and Class III medical devices, clinical evaluation is mandatory, reflecting the higher risks associated with these categories. The requirements vary based on the device’s application scope and associated risks, ensuring that each device is rigorously assessed for safety and effectiveness before entering the Chinese market.
Exemptions from Clinical Evaluation
While clinical evaluation is generally required for registration and filing, exemptions are possible under certain conditions:
1
The device has a clear working mechanism, standardized design, and mature production process; similar devices have been marketed and used clinically for years without reports of serious adverse events, and the intended use has not changed.
2
Safety and effectiveness can be proven through non-clinical evaluation methods.
It is essential for manufacturers to verify their product's status against the clinical trial exemption list to determine the appropriate regulatory pathway.
Products meeting exemption criteria are not required to submit clinical evaluation materials. The NMPA publishes and updates the official exemption lists for:
Additionally, the exemption catalogue plays a crucial role in determining eligibility for an exempted pathway for Class II and III devices. Manufacturers should regularly check the NMPA's updates to ensure compliance.
Clinical Evaluation of Medical Devices
There are two primary pathways for clinical evaluation:
1
Same Type Pathway (Predicate Approach)
2
Clinical Trial Pathway
Additionally, the exemption catalogue plays a crucial role in determining eligibility for an exempted pathway for Class II and III devices. Manufacturers should regularly check the NMPA's updates to ensure compliance.
1
Same Type Device Pathway
Many medical devices are developed incrementally rather than through radical innovation. In such cases, clinical evaluation can be based on existing clinical data and non-clinical studies of similar products already approved by NMPA. The importance of compared devices in the evaluation process cannot be overstated, as they provide a benchmark for assessing new products.
A “same type” or predicate device must:
Detailed information on the predicate device is required, including production process details (especially for non-active products). Because predicate data is often proprietary, this route is typically best suited for companies that already have similar products registered in China. Demonstrating substantial equivalence with an equivalent device is crucial for the Clinical Evaluation Report (CER), as it can help avoid the need for new clinical trials in China. Although applicants may request information from NMPA, data owners are rarely willing to share sensitive details with competitors.
2
Clinical Trial Pathway
If the product differs significantly in intended use, technology, or biological characteristics compared to existing approved devices, it is classified as a new type of medical device and will require clinical trial data.
Depending on the source of clinical trial data conducted, the latter pathway includes:
1
2
Multi-Pathway Evaluation
If one pathway alone is insufficient to support the registration, multiple data sources (e.g., partial clinical data, predicate comparison, literature, non-clinical data) can be combined to meet NMPA requirements.
Clinical Evaluation of In Vitro Diagnostic (IVD) Reagents
For IVD products exempt from clinical trials, clinical evaluation must still confirm the product meets its intended use. This may involve:
Additionally, the evaluation process includes essential comparison tables to assess eligible devices listed in the NMPA 'Exemption Catalogue.'
If substantial equivalence or adequate consistency cannot be demonstrated, the product must undergo clinical trials.
For IVDs not exempt from clinical trials, manufacturers must generate and submit clinical trial data for registration.
NMPA Clinical Evaluation Report Regulations & Requirements
The National Medical Products Administration (NMPA) has established stringent regulations and requirements for clinical evaluation reports. These regulations are designed to ensure that all medical devices meet high standards of safety and effectiveness. The NMPA requires detailed documentation of clinical data, including clinical trials, clinical literature reviews, and clinical experience data. Compliance with these regulations is essential for successful registration and market entry of medical devices in China. Manufacturers must ensure that their CERs are meticulously prepared to meet NMPA standards, providing clear evidence of the device’s clinical performance and safety.
Our China Clinical Evaluation Report Services for Medical Devices & IVDs
We specialize in preparing CERs that comply with NMPA standards, helping you streamline the registration process and, where possible, avoid the need for local clinical trials. Our services include:
Regulatory Assessment & Strategy
CER Preparation & Documentation
Data Collection & Analysis
Submission & NMPA Compliance Support
Explore Cisema's Related Services
Whether you’re just starting out or are a blue-chip, access our wide range of services and solutions to help your business thrive.
China Medical Device Registration
We guide you through every step of the China medical device registration and filing process. We take care of compliance with NMPA requirements, advising you on the optimal market entry pathway, and helping you through the whole process.
China NMPA IVD Registration
We support you through every stage of the China IVD registration and filing process, ensuring compliance with NMPA regulations. From choosing the best market entry strategy to handling regulatory requirements, we make the process as smooth as possible.
China Clinical Trials
You may be required to provide supplementary clinical data on Chinese patients or conduct a full clinical trial in China.Our clinical research team will advise you, prepare the study protocol and assist setting up the clinical trial in China.
NMPA Type Testing
Our on-site test engineers coordinate and supervise type tests of your medical devices in NMPA-accredited laboratories.
Drug Device Combination Products
We assist with the classification, registration, and compliance of combination products in China, whether drug or device led.
China Medical Device Quality Compliance
We help you achieve and ensure ongoing compliance with Chinese requirements. Our experts prepare and assist you for official NMPA inspections.
Medical Device PMS & Vigilance
The NMPA is placing greater focus on Post-Market Surveillance (PMS) such as more in-market sampling inspections and regular standard changes.Our specialist PMS team means you stay up to date with the many aspects of compliance.
Regulatory Outsourcing
If you are seeking specific specialist expertise or have ongoing resource-intensive needs, we have a variety of solutions to meet your needs.
NMPA Legal Agent
We are your authorized representative in China, and fulfill your registrations and filings as well as ensuring compliance with quality and PMS requirements.
